the game is ON

Here it comes. It now makes sense the share price tanked to $10.02 despite all the good news! Because it's been played!

The rising star in the Australian listed healthcare industry, Neuren Pharmaceuticals, is understood to have brought in a defence adviser after fielding buyer interest from US-based industry giants. DataRoom understands that Jefferies has won the mandate.Neuren is being targeted by US pharmaceutical companies because it offers a unique solution for a rare disease and has hit all of its milestones. The business operates in the sweet spot of a number of private equity firms such as Blackstone, which is targeting life sciences investments in a quest to capitalise on the growing demand for healthcare. Also, because neurodevelopmental disorders are serious conditions with unmet needs, drugs being developed to treat them may qualify for favourable regulatory pathways intended to expedite the development and approval of therapeutically important drugs.